Figure 4

Aβ12-28P treatment reduces soluble and insoluble brain apoE levels and apoE deposition in Aβ plaques in APP/E2 and APP/E4 mice. Levels of soluble (diethylamine-extractable) human apoE (A) and those of insoluble (formic-acid-extractable) human apoE (B). Values are mean (±SEM) in 11–12 animals of APP/E2 background and 8 animals of APP/E4 background. (C) Representative microphotographs of coronal sections through the sensorimotor cortex at the level of the posterior caudate-putamen from vehicle- and Aβ12-28P-treated APP/E2 and APP/E4 mice, which were immunostained against human apoE. White arrowheads indicate apoE positive deposits. (D) Mean (±SEM) human apoE positive plaque load in the neocortex and the hippocampus (n = 7–8/group). (A, B, D) * p < 0.05, ** p < 0.01, *** p < 0.001, *** p < 0.0001, versus vehicle-treated mice of the same APOE background (Student’s t test). ^## p < 0.01, ^#### p < 0.0001, vehicle-treated APP/E2 mice vs. vehicle-treated APP/E4 mice (Student’s t test). Scale bar 200 μm (C). Abbreviations: cc, corpus callosum; CPu, caudate-putamen; NCtx, neocortex.